Enhancement of the 5-HT neurotransmission by antidepressant treatments.
The hypothesis of an etiopathogenic role of 5-HT and that of a mediation by the 5-HT system in the effect of antidepressant treatments have often been confused. Little unequivocal evidence exists for a 5-HT deficit in depression. However, several recent animal and clinical data suggest that the 5-HT system might contribute to the therapeutic effect of various antidepressant treatments. Long-term administration of tricyclic antidepressant (TCA) drugs induces a sensitization of rat forebrain neurons to iontophoretically-applied 5-HT. Repeated electroconvulsive shocks result also in an increased sensitivity of forebrain 5-HT receptors. However, chronic administration of a new antidepressant drug, zimelidine, a potent and long-lasting 5-HT uptake blocker, fails to modify 5-HT receptor sensitivity. These results suggest that enhancement of 5-HT neurotransmission obtained via either pre- or postsynaptic mechanisms might determine the antidepressant effect of these treatments. In a recent clinical study, we observed that lithium administration to TCA-resistant depressive patients induced a rapid relief of depression. It is possible that the presynaptic enhancing effect of lithium on the 5-HT system might unveil the TCA-induced sensitization of the postsynaptic 5-HT receptors. Most depressed patients exhibit marked diurnal variations of mood. Preliminary experiments in rats revealed that the responsiveness of hippocampal neurons to iontophoretically-applied 5-HT is enhanced in the evening. Similar diurnal variations of 5-HT receptor sensitivity might occur in human brain and be related to diurnal variation of mood in depression. Since normal individuals do not show these fluctuations of mood, it is proposed that the "mood regulating system" might become 5-HT dependent in depressed patients.
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001977:Brompheniramine / Q000031:analogs & derivatives / Q000494:pharmacology; D002940:Circadian Rhythm; D003863:Depression / Q000188:drug therapy / Q000628:therapy; D004565:Electroconvulsive Therapy; D004644:Emotions; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D008960:Models, Psychological; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D011903:Raphe Nuclei / Q000502:physiology; D011985:Receptors, Serotonin / Q000502:physiology; D012701:Serotonin / Q000502:physiology*; D009435:Synaptic Transmission / Q000187:drug effects*; D015031:Zimeldine
D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic; D011985:Receptors, Serotonin; D012701:Serotonin; D015031:Zimeldine; D008094:Lithium; D001977:Brompheniramine